S
Spencer D. Martin
Researcher at University of British Columbia
Publications - 18
Citations - 1375
Spencer D. Martin is an academic researcher from University of British Columbia. The author has contributed to research in topics: Cancer & Immune system. The author has an hindex of 10, co-authored 16 publications receiving 1182 citations. Previous affiliations of Spencer D. Martin include BC Cancer Agency & University of Victoria.
Papers
More filters
Journal ArticleDOI
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
Scott D. Brown,Scott D. Brown,René L. Warren,Ewan A. Gibb,Ewan A. Gibb,Spencer D. Martin,Spencer D. Martin,John J. Spinelli,John J. Spinelli,Brad H. Nelson,Brad H. Nelson,Brad H. Nelson,Robert A. Holt,Robert A. Holt,Robert A. Holt +14 more
TL;DR: For 515 patients from six tumor sites, RNA-seq data from The Cancer Genome Atlas was used to identify mutations that were predicted to be immunogenic in that they yielded mutational epitopes presented by the MHC proteins encoded by each patient's autologous HLA-A alleles that were associated with increased patient survival.
Journal ArticleDOI
Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer
Nathan R. West,Sara E. Kost,Sara E. Kost,Spencer D. Martin,Spencer D. Martin,Katy Milne,R. J. deLeeuw,Brad H. Nelson,Peter H. Watson,Peter H. Watson,Peter H. Watson +10 more
TL;DR: In contrast with current dogma, this work shows for the first time that FOXP3+ TIL are associated with robust anti-tumour immunity and favourable prognosis in ER– breast cancer.
Journal ArticleDOI
Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer
Darin A. Wick,John R. Webb,Julie S. Nielsen,Spencer D. Martin,David R. Kroeger,Katy Milne,Mauro Castellarin,Kwame Twumasi-Boateng,Peter H. Watson,Robert A. Holt,Brad H. Nelson +10 more
TL;DR: The findings reveal the limitations of spontaneous tumor immunity in the setting of standard treatments and suggest a high degree of ignorance of tumor mutations that could potentially be reversed by immunotherapy.
Journal ArticleDOI
Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.
Spencer D. Martin,Spencer D. Martin,Scott D. Brown,Darin A. Wick,Julie S. Nielsen,David R. Kroeger,Kwame Twumasi-Boateng,Robert A. Holt,Robert A. Holt,Brad H. Nelson,Brad H. Nelson,Brad H. Nelson +11 more
TL;DR: The findings highlight the limitations of applying neoantigen-targeted vaccines to tumor types with intermediate/low mutation burdens and highlight the need to understand more fully the rationale behind the selection of these vaccines.
Journal ArticleDOI
Combined immunodeficiency associated with homozygous MALT1 mutations
Margaret L. McKinnon,Jacob Rozmus,Shan-Yu Fung,Aaron F. Hirschfeld,Kate L. Del Bel,Leah T Thomas,Nico Marr,Spencer D. Martin,Ashish Marwaha,John J. Priatel,Rusung Tan,Christof Senger,Angela Tsang,Julie S. Prendiville,Anne K. Junker,Michael Seear,Kirk R. Schultz,Laura M. Sly,Robert A. Holt,Millan S. Patel,Jan M. Friedman,Stuart E. Turvey +21 more